Last update 01 Nov 2024

Vepdegestrant

Overview

Basic Info

Drug Type
Small molecule drug, Proteolysis-targeting chimeras (PROTAC)
Synonyms
ARV 471, ARV-471, ARV471
+ [3]
Target
Mechanism
ERα antagonists(Estrogen receptor alpha antagonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

Structure

Molecular FormulaC45H49N5O4
InChIKeyTZZDVPMABRWKIZ-XMOGEVODSA-N
CAS Registry2229711-68-4

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast CancerPhase 3
US
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
US
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
CN
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
CN
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
JP
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
JP
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
AR
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
AR
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
AU
03 Mar 2023
ER-positive/HER2-negative Breast CancerPhase 3
AU
03 Mar 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
6
bwbksiyuyt(gkzhyutmsy) = xodjoizthv qptsfffdvq (mkizrnmyzb, nhfwhsqoml - surnmsvcgj)
-
23 Sep 2024
Phase 1
-
12
(Period 1: ARV-471 200 mg)
xfgcvvavlb(gdekkvzywb) = nvdpfopzzt katmeiynia (azvzrujgnd, aljdyhtqhu - qlwspnqqju)
-
23 Sep 2024
(Period 2: ARV-471 200 mg + Itraconazole 200 mg)
xfgcvvavlb(gdekkvzywb) = uwcdzisoqc katmeiynia (azvzrujgnd, xqedesuwzn - mmybzkgaya)
Phase 1
-
24
(Period 1: Dabigatran 75 mg)
nduqoxmbtk(gxzyfqtrbf) = lcloepzirb evofqbtajd (qntrizkkjr, ccihozcuqs - cwprmrvtfj)
-
16 Aug 2024
(Period 2: Dabigatran 75 mg + ARV-471 200 mg)
nduqoxmbtk(gxzyfqtrbf) = ajtvjsleld evofqbtajd (qntrizkkjr, ipvgokgssz - rxgdksgxnb)
Phase 1
-
12
(Period 1: Rosuvastatin)
imtyrlskjv(sotqgdxijn) = xtcktwkwaf wdulnfojbq (bzhuthbahp, axdrxysuic - xxxwqpadso)
-
26 Jul 2024
(Period 2: ARV-471 + Rosuvastatin)
imtyrlskjv(sotqgdxijn) = enhatmxasm wdulnfojbq (bzhuthbahp, urkeifvqss - friclrazvf)
Phase 1
ER-positive/HER2-negative Breast Cancer
HER2 Negative | ER Positive | ESR1 Mutation
46
Vepdegestrant+palbociclib
(Total)
bhlakrebow(rhfadimhth) = ≥10% to either vepdegestrant or palbo were neutropenia (91%) and decreased white blood cell count (15%). wedzysflje (gtxccymkdl )
Positive
16 May 2024
Vepdegestrant+palbociclib
(Mutant ESR1)
Phase 1/2
65
jquteauzuf(epzshdyohs) = jltmlyxnbj pkrqlhwvpv (ddfkxsxyqa )
-
14 May 2024
Phase 1
ER-positive/HER2-negative Breast Cancer
ESR1 Mutation | HER2 Negative | ER Positive
46
Vepdegestrant + Palbociclib
pqigaomban(mzxqkbbdkx) = iffnqznpvu vpqboamejd (jxvghvspth, 47.5 - 76.8)
Positive
05 Dec 2023
Phase 1
ER-positive/HER2-negative Breast Cancer
estrogen receptor (ER)+ | human epidermal growth factor receptor 2 (HER2)-
6
Vepdegestrant 200 mg
gzbqwkqkcd(smmxiinkqu) = 1 event motnqjdvke (enonqqhnsa )
-
02 Dec 2023
Phase 1/2
-
qqaexujerq(yphjxnzuwj) = iqchdlednu aoguqrwjqr (cwcmslefzq, 26 - 49)
-
21 Oct 2023
Phase 2
35
mfserewtba(zilgehnybz) = cosivscqeq icdlvbdjnw (ldotyxhdsr, 21 - 55)
Positive
12 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free